热门资讯> 正文
Tiziana股价在foralumab数据公布日上涨
2025-06-13 21:36
- Tiziana Life Sciences (NASDAQ:TLSA) shares rose on Friday after the company said that its CEO, Ivor Elrifi, will present data related to its lead drug candidate, intranasal foralumab, for the treatment of neuroinflammation.
- The CEO is set to give the oral presentation during the Bio International Convention in Boston for anti-CD3 monoclonal antibody, foralumab, on June 18, at 11:45 AM ET.
- The stock is up 7% premarket.
More on Tiziana Life Sciences
- Tiziana posts favorable PET scan data for lead asset in Alzheimer's
- Tiziana rises on positive results in multiple sclerosis treatment study
- Financial information for Tiziana Life Sciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
